Extended treatment with tenofovir disoproxil fumarate in treatment-Experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 15-21

  Margot, Nicolas A ^a   Isaacson, Erica ^a   McGowan, Ian ^a,b   Cheng, Andrew ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV 1; Mutation; NRTI; Tenofovir

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA EXTRACTION; VIRUS GENE; VIRUS LOAD;

EID: 0038372726     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00003     Document Type: Article

References (13)

1. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyl-oxymethylcarbonyl) PMPA. Antimicrob Agents Chemother. 1998;42: 612-617.
2. Robbins BL, Greenhaw JJ, Connelly MC, et al. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother. 1995;39:2304-2308.
3. Miller MD, Margot NA, Hertogs K, et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. Nucleosides, Nucleotides & Nucleic Acids. 2001;20:1025-1028.
4. Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother. 1998;42: 1484-1487.
5. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. 1999;4:87-94.
6. Gu Z, Gao Q, Fang H, et al. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1994;38:275-281.
7. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1994;38:282-287.
8. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997;41:1094-1098.
9. De Antoni A, Foli A, Lisziewicz J, et al. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis. 1997;176:899-903.
10. Bloor S, Kemp SD, Hertogs K, et al. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12000 samples from the USA in 1999. Antiviral Ther. 2000;5:132.
11. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-1263.
12. Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-1235.
13. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M 184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother. 2002;46:3437-3446.